Baseline demographics, disease characteristics, and laboratory values (N = 41)
| Characteristic . | Value . |
|---|---|
| Median age, y (range) | 68 (18-90) |
| Male sex, no. (%) | 27 (66) |
| AML, no. (%) | 31 (76) |
| CLL, no. (%) | 4 (10) |
| MDS, no. (%) | 3 (7) |
| ALL, no. (%) | 2 (5) |
| CML, no. (%) | 1 (2) |
| Median no. of prior treatments (range) | 2 (0-7) |
| Median white blood cell count, × 109/L (range) | 2.1 (0.2-87.7) |
| Median hemoglobin, g/L (range) | 94 (74-126) |
| Median absolute neutrophil count, × 109/L (range) | 0.5 (0-10.1) |
| Median platelet count, × 109/L (range) | 36 (5-232) |
| Median bilirubin, μmol/L (range) | 5.8 (4.6-7.8) |
| Median aspartate aminotransferase, units/L (range) | 25.5 (0-85) |
| Median alanine aminotransferase, units/L (range) | 22.5 (12-148) |
| Median creatinine, μmol/L (range) | 8.6 (3.4-15.4) |
| Cytogenetics, no. (%) | |
| Diploid | 11 (27) |
| Core binding factor | 1 (2) |
| Other | 29 (71) |
| Characteristic . | Value . |
|---|---|
| Median age, y (range) | 68 (18-90) |
| Male sex, no. (%) | 27 (66) |
| AML, no. (%) | 31 (76) |
| CLL, no. (%) | 4 (10) |
| MDS, no. (%) | 3 (7) |
| ALL, no. (%) | 2 (5) |
| CML, no. (%) | 1 (2) |
| Median no. of prior treatments (range) | 2 (0-7) |
| Median white blood cell count, × 109/L (range) | 2.1 (0.2-87.7) |
| Median hemoglobin, g/L (range) | 94 (74-126) |
| Median absolute neutrophil count, × 109/L (range) | 0.5 (0-10.1) |
| Median platelet count, × 109/L (range) | 36 (5-232) |
| Median bilirubin, μmol/L (range) | 5.8 (4.6-7.8) |
| Median aspartate aminotransferase, units/L (range) | 25.5 (0-85) |
| Median alanine aminotransferase, units/L (range) | 22.5 (12-148) |
| Median creatinine, μmol/L (range) | 8.6 (3.4-15.4) |
| Cytogenetics, no. (%) | |
| Diploid | 11 (27) |
| Core binding factor | 1 (2) |
| Other | 29 (71) |
AML indicates acute myeloid leukemia; CLL, chronic lymphocytic leukemia; MDS, myelodysplastic syndromes; ALL, acute lymphoblastic leukemia; and CML, chronic myelocytic leukemia.